The company went public at a time that the Renaissance IPO ETF has gained 2.9% over the past three months, while the S&P 500 has lost 12.0%.Inari Medical Inc. increased that number of shares it was selling in its initial public offering, which priced late Thursday above the expected range.
The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA. Inari Medical's stock indicated to open at $41.31, or 117% above $19 IPO price May. The company is looking to go public at a time that the Renaissance IPO ETF has gained 2.5% over the past three months while the S&P 500 has lost 11.0%.Lemonade's 140% IPO debut was one of the best of 2020, but it raises questionsStocks To Watch: Spotlight On EVs, Shipping And HertzWeekly CEO Buys Highlight: OPKO Health, Inari MedicalThe Violence Isn't Likely To Perturb The Market, What Might Cause A Sell-Off Is...Inari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesInari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesInari Medical Announces Pricing of Its Upsized Initial Public OfferingInari Medical Announces Pricing of Its Upsized Initial Public Offering The Irvine, Calif.-based company expects its stock to be listed on the Nasdaq exchange under the ticker symbol "NARI."
The Irvine, Calif.-based company, which develops medical devices for patients suffering from venous diseases, upsized its IPO to 8.20 million shares from 7.33 million shares… The company, which develops medical devices for patients suffering from venous diseases, is still offering 7,333,000 shares in the IPO, so the amount it can raise has increased to $132.0 million from $117.3 million. The Irvine, Calif.-based company, which develops medical devices for patients suffering from venous diseases, upsized its IPO to 8.20 million shares from 7.33 million shares. Inari’s management is scheduled to present on Wednesday, August 12 at 4:30 p.m. Eastern Time. The company recorded net income of $4.1 million on revenue of $27.0 million in the first quarter, after a loss of about $948,000 on revenue of $6.9 million a year ago. The live webinar of the call may be accessed by visiting the Events section of Inari's website at ir.inarimedical.com. It develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. The stock is expected to begin trading on the Nasdaq exchange Friday. Add to Watchlist. NARI: Get the latest Inari Medical stock price and detailed information including NARI news, historical charts and realtime prices. Find the latest Inari Medical, Inc. (NARI) stock quote, history, news and other vital information to help you with your stock trading and investing. BofA Securities, Morgan Stanley and Wells Fargo Securities are the lead underwriters. Interested parties may access the live call via telephone by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 6859088. By using this site you agree to the Inari Medical, Inc. operates as a medical device company. Copyright © 2020 MarketWatch, Inc. All rights reserved. Currency in USD
";s:7:"keyword";s:25:"inari medical stock price";s:5:"links";s:1088:"Thermistor Circuit To Measure Temperature, Homes For Sale In Castleford Idaho, Uav Helicopter For Sale, Rain 5g Review 2020, Never Meant To Be Meaning, Never Meant To Be Meaning, How To Get Taunts In Tf2, Data Glitch 2 Serial Number, East Ardsley Yorkshire, Terraform Azure Pipeline Yaml, ";s:7:"expired";i:-1;}